MediPharm Labs Yönetim

Yönetim kriter kontrolleri 3/4

MediPharm Labs' CEO'su David Pidduck, Apr2022 tarihinde atandı, in görev süresi 2.5 yıldır. in toplam yıllık tazminatı CA$ 1.31M olup, şirket hissesi ve opsiyonları dahil olmak üzere 36% maaş ve 64% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.08% ine doğrudan sahiptir ve bu hisseler CA$ 1.09M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5 yıl ve 5.3 yıldır.

Anahtar bilgiler

David Pidduck

İcra Kurulu Başkanı

CA$1.3m

Toplam tazminat

CEO maaş yüzdesi	36.0%
CEO görev süresi	2.5yrs
CEO sahipliği	4.1%
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

Oct 11

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11

CEO Tazminat Analizi

David Pidduck'un ücretlendirmesi MediPharm Labs'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CA$13m
Mar 31 2024	n/a	n/a	-CA$14m
Dec 31 2023	CA$1m	CA$470k	-CA$13m
Sep 30 2023	n/a	n/a	-CA$16m
Jun 30 2023	n/a	n/a	-CA$20m
Mar 31 2023	n/a	n/a	-CA$26m
Dec 31 2022	CA$3m	CA$315k	-CA$30m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 967.31K ), Canadian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 177.89K ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Pidduck

2.5yrs

Görev süresi

CA$1,305,051

Tazminat

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Pidduck	CEO & Director	2.5yrs	CA$1.31m	4.08% CA$ 1.3m
Keith Strachan	Co-Founder & President	5.7yrs	CA$819.48k	2.17% CA$ 668.8k
Greg Hunter	Chief Financial Officer	3.7yrs	CA$957.75k	0.31% CA$ 97.0k
Patrick McCutcheon	Founder	9.8yrs	CA$858.16k	Veri yok
Brett Moon	Vice President of Sales	4.4yrs	Veri yok	Veri yok
Kirk Binns	Executive Vice President of Global Accounts	5.7yrs	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: LABS 'un yönetim ekibi deneyimli ve deneyimlidir ( 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Pidduck	CEO & Director	2.5yrs	CA$1.31m	4.08% CA$ 1.3m
Shelley Martin	Independent Director	4.3yrs	CA$64.49k	0.020% CA$ 6.0k
Michael Bumby	Independent Director	1.5yrs	CA$34.45k	0.050% CA$ 15.4k
Christopher Taves	Independent Chairman of the Board	4.3yrs	CA$87.14k	0.35% CA$ 106.7k
Miriam McDonald	Member of the Science Advisory Board	5.5yrs	CA$32.40k	Veri yok
Leslie Brown	Member of the Science Advisory Board	5.5yrs	Veri yok	Veri yok
Matt Archibald	Member of the Science Advisory Board	5.5yrs	Veri yok	Veri yok
Markus Roggen	Member of the Science Advisory Board	5.5yrs	Veri yok	Veri yok
Arshad Hack	Member of the Science Advisory Board	5.5yrs	Veri yok	Veri yok
Jerry King	Member of the Science Advisory Board	5.5yrs	Veri yok	Veri yok
Carolina Landolt-Marticorena	Member of the Science Advisory Board	5.2yrs	Veri yok	Veri yok
Christopher Halyk	Independent Director	4.2yrs	CA$56.05k	0.043% CA$ 13.2k

5.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: LABS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

MediPharm Labs Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

MediPharm Labs Corp. Announces Executive Changes

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

CEO & Director exercised options to buy CA$130k worth of stock.

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

High number of new and inexperienced directors

Recent updates

MediPharm Labs Corp. Announces Executive Changes

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations

MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

MediPharm Labs (TSE:LABS) Is Using Debt Safely

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

Consensus estimates of losses per share improve by 25%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

New minor risk - Share price stability

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 11%

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

CEO & Director exercised options to buy CA$130k worth of stock.

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

Consensus EPS estimates upgraded to CA$0.045 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Consensus revenue estimates increase by 47%, EPS downgraded

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Consensus revenue estimates fall by 20%

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to CA$0.25

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Consensus revenue estimates fall by 13%

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold CA$87k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)